How Much Does Insulin Degludec Cost?
The cost of insulin degludec can vary significantly based on factors such as insurance coverage, dosage, and pharmacy. Patients may pay between \$400 and \$700 for a 10-mL vial or a package of three 3-mL pens. Without insurance, a single pen of insulin degludec can range from approximately \$125 to \$135.
How Can I Lower the Cost of Insulin Degludec?
Several strategies can help reduce the out-of-pocket expenses for insulin degludec. These include utilizing manufacturer coupons, exploring patient assistance programs, and comparing prices at different pharmacies. Generic versions, when available, can also offer significant savings.
What is the Cost Difference Between Insulin Degludec and Other Insulins?
Insulin degludec is a long-acting basal insulin. Its cost is generally comparable to other modern long-acting insulins, such as insulin glargine (Lantus, Basaglar) and insulin detemir (Levemir). However, older and less expensive insulin formulations, like neutral protamine Hagedorn (NPH) insulin or regular human insulin, are typically more affordable. The specific cost difference will depend on the brand, formulation, and whether a generic option is available.
When Does Insulin Degludec's Patent Expire?
The patent exclusivity for insulin degludec (Tresiba) and its delivery device (FlexTouch pen) is expected to expire in 2027. This expiration date opens the door for potential generic or biosimilar competition in the market, which could lead to reduced prices for consumers. You can find more information on patent expirations and exclusivity timelines on DrugPatentWatch.com [1].
Who Makes Insulin Degludec?
Insulin degludec is manufactured by Novo Nordisk. It is marketed under the brand name Tresiba for injection and also as part of a combination product with insulin aspart called Ryzodeg [2].
What Are the Side Effects of Insulin Degludec?
Like all insulins, the most common side effect of insulin degludec is hypoglycemia, or low blood sugar. Other potential side effects include injection site reactions (redness, itching, swelling), lipodystrophy (changes in fat tissue at the injection site), and allergic reactions. Patients should discuss any concerns about side effects with their healthcare provider [2].
Can Biosimilars of Insulin Degludec Be Available Before Patent Expiry?
While biosimilar pathways exist for biologic drugs, the timeline for biosimilar entry is often tied to patent and exclusivity periods. For insulin degludec, significant biosimilar competition is generally anticipated after the patent expiry in 2027. However, specific legal challenges or regulatory interpretations could influence this timeline.
Sources:
1. DrugPatentWatch.com
2. Novo Nordisk